🇺🇸 FDA
Patent

US 8778949

1-(2-phenoxymethylphenyl)piperazine compounds

granted A61KA61K31/495A61P

Quick answer

US patent 8778949 (1-(2-phenoxymethylphenyl)piperazine compounds) held by Theravance Biopharma R&D IP, LLC expires Mon Jul 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance Biopharma R&D IP, LLC
Grant date
Tue Jul 15 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K31/495, A61P, A61P13/00, A61P19/02